Yüklüyor......
TRAIL-R2-specific antibodies and recombinant TRAIL can synergise to kill cancer cells
TRAIL induces apoptosis in cancer cells whilst sparing normal tissues. Despite promising pre-clinical results, few patients responded to treatment with recombinant TRAIL (Apo2L/Dulanermin) or TRAIL-R2-specific antibodies, such as conatumumab (AMG655). It is unknown whether this was due to intrinsic...
Kaydedildi:
| Yayımlandı: | Oncogene |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2014
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4240732/ https://ncbi.nlm.nih.gov/pubmed/24909167 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2014.156 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|